Abstract:Background: Rubella is a contagious viral infection that occurs most often in children and young adults. Rubella is the leading vaccine-preventable cause of birth defects. Rubella infection in pregnant women may cause fetal death or congenital defects known as congenital rubella syndrome. There is no specific treatment for rubella, but the disease is preventable by vaccination with an efficacy of over 95%. Vaccination coverage is still below the recommended levels and many cases have occurred worldwide. The COVID-19 pandemic has had a negative impact on the immunization programs and the quality of disease surveillance worldwide. Operators of the healthcare setting are at increased risk of infection due to their work duties and should receive preventive vaccination or serologic protection to work in a healthcare setting. Aims: To evaluate the serological evidence of rubella IgG antibodies in female healthcare operators of childbearing age, to assess the risk of a breakthrough infection and the need for an additional dose of vaccine. Methods: We collected age and antibody titers from 449 young female operators aged <50 years who underwent the periodic surveillance at the Occupational Medicine Unit of the Policlinico Tor Vergata, Rome, from January to July 2022. Subjects were considered immune if the anti-rubella IgG titer was >11.00 IU/mL. Results: The rate of serologically unprotected subjects was 9.13% (41/449). The mean age of protected subjects was 26.93 years, while the mean age of unprotected subjects was 28.24 years. Age did not correlate with mean titer on statistical analysis (p = 0.10). The acceptance rate among unprotected operators was 31.7%. A positive attitude towards vaccination was found in 11/28 (39.3%) of the unvaccinated subjects, while a negative tendency was found in 2/28 (7.1%) of these subjects; most of the unvaccinated operators 15/28 (53.6%) prefer to postpone the administration of the vaccine. When compared with a similar population from the pre-pandemic period, the actual proportion of immune female subjects was not significantly different from that found in 2019 (90.87% vs. 90.3%). Conclusions: Protection against rubella was suboptimal among female healthcare workers of childbearing age. Acceptance of the rubella vaccine among these operators was low. Most of those who were hesitant intended to postpone the vaccination, while a minority had negative attitudes toward vaccination. A policy of mandatory vaccination policy should overcome the reluctance of operators.

Report from the World Health Organization's immunization and vaccines-related implementation research advisory committee (IVIR-AC) ad hoc meeting, 28 June – 1 July 2024

Report from the World Health Organization's Immunization and Vaccines-Related Implementation Research Advisory Committee (IVIR-AC) Meeting, Virtual Gathering, 10–13 September 2024

Report from the World Health Organization’s Immunization and Vaccines-Related Implementation Research Advisory Committee (IVIR-AC) Meeting, Virtual Gathering, 26 February–1 March 2024

February 2024 ACIP Meeting Update: Meningococcal, RSV, COVID-19, and Other Vaccines

June 2024 ACIP Meeting Update: Influenza, COVID-19, RSV, and Other Vaccines

Introduction of rubella-containing-vaccine to Madagascar: implications for roll-out and local elimination

Report on WHO meeting on immunization in older adults: Geneva, Switzerland, 22–23 March 2017

Use of existing systematic reviews for the development of evidence-based vaccination recommendations: Guidance from the SYSVAC expert panel

Global Status Report for the Verification of Measles and Rubella Elimination, 2022

The impact of sub-national heterogeneities in demography and epidemiology on the introduction of rubella vaccination programs in Nigeria

How to prevent rubella epidemics and congenital rubella syndrome: lessons from 42 years of longitudinal epidemiology in Osaka Prefecture, Japan (1982-2023)

Tracking Measles and Rubella Elimination Progress—World Health Organization African Region, 2022–2023

Rubella Vaccine Uptake among Women of Childbearing Age in Healthcare Settings

Progress and Challenges in Measles and Rubella Elimination in the WHO European Region

Meeting report of the 37th International Conference on Antiviral Research in Gold Coast, Australia, May 20–24, 2024, organized by the International Society for Antiviral Research

EULAR/PRES recommendations for vaccination of paediatric patients with autoimmune inflammatory rheumatic diseases: update 2021

A review of vaccine research and development: Human acute respiratory infections

Accelerating Global Measles and Rubella Eradication—Saving Millions of Lives, Preventing Disability, and Averting the Next Pandemic

Shaping global vaccine acceptance with localized knowledge: a report from the inaugural VARN2022 conference

Rubella epidemiology in Lesotho after vaccine introduction: a five-year review, 2018-2022

2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases